We are live on ! Find out more
AUPH icon

Aurinia Pharmaceuticals
AUPH

68 hedge funds and large institutions have $108M invested in Aurinia Pharmaceuticals in 2017 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 17 increasing their positions, 15 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

43% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 14

13% more repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 15

10% more funds holding

Funds holding: 62 → 68 (+6)

0.32% more ownership

Funds ownership: 28.06% → 28.38% (+0.32%)

27% less capital invested

Capital invested by funds: $147M → $108M (-$39M)

71% less call options, than puts

Call options by funds: $865K | Put options by funds: $2.99M

Holders
68
Holders Change
+6
Holders Change %
+9.68%
% of All Funds
1.54%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
20
Increased
17
Reduced
15
Closed
14
Calls
$865K
Puts
$2.99M
Net Calls
-$2.12M
Net Calls Change
+$1.29M

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$4M
2
PC
Polar Capital
United Kingdom
+$3.78M
3
Point72 Asset Management
Point72 Asset Management
Connecticut
+$2.98M
4
Franklin Resources
Franklin Resources
California
+$2.3M
5
Goldman Sachs
Goldman Sachs
New York
+$1.77M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$5.74M
2
CLCM
Crawford Lake Capital Management
New Jersey
-$2.86M
3
RG
Redmile Group
California
-$2.08M
4
SC
Sculptor Capital
New York
-$1.16M
5
Morgan Stanley
Morgan Stanley
New York
-$1.13M
Name Holding Trade Value Shares
Change 		Change in
Stake
Bank of Montreal
26
Bank of Montreal
Ontario, Canada
$419K -$193K -34,852 -27%
ARTA
27
A.R.T. Advisors
New York
$300K +$368K +66,365 New
Renaissance Technologies
28
Renaissance Technologies
New York
$242K -$29.4K -5,300 -9%
CCM
29
Cutler Capital Management
Massachusetts
$226K +$55.5K +10,000 +25%
Two Sigma Advisers
30
Two Sigma Advisers
New York
$219K -$39.4K -7,100 -13%
SIM
31
Spark Investment Management
New York
$153K +$187K +33,700 New
ProShare Advisors
32
ProShare Advisors
Maryland
$130K +$160K +28,783 New
RJFSA
33
Raymond James Financial Services Advisors
Florida
$120K -$68.8K -12,400 -32%
Geode Capital Management
34
Geode Capital Management
Massachusetts
$112K – – –
Millennium Management
35
Millennium Management
New York
$110K -$85.5K -15,397 -39%
SOMRS
36
State of Michigan Retirement System
Michigan
$102K – – –
DTL
37
Dynamic Technology Lab
Singapore
$96K +$117K +21,093 New
Wells Fargo
38
Wells Fargo
California
$89K -$38.9K -7,000 -26%
CS
39
Credit Suisse
Switzerland
$87K +$107K +19,279 New
ICA
40
Infrastructure Capital Advisors
New York
$87K +$107K +19,303 New
Royal Bank of Canada
41
Royal Bank of Canada
Ontario, Canada
$77K +$3.36K +606 +4%
Vanguard Group
42
Vanguard Group
Pennsylvania
$67K +$82K +14,771 New
NFG
43
Noven Financial Group
Colorado
$66K +$3.61K +650 +5%
PFGIA
44
Patriot Financial Group Insurance Agency
Massachusetts
$57K +$61.6K +11,100 New
Bank of New York Mellon
45
Bank of New York Mellon
New York
$52K +$64.7K +11,657 New
MOS
46
MGO One Seven
Ohio
$50K +$61.1K +11,000 New
Stifel Financial
47
Stifel Financial
Missouri
$49K +$60.8K +10,946 New
Invesco
48
Invesco
Georgia
$48K +$58.7K +10,578 New
LCS
49
Levin Capital Strategies
New York
$45K – – –
Deutsche Bank
50
Deutsche Bank
Germany
$42K -$245K -44,174 -82%
1
2
3 4

AUPH Hedge Fund Activity: Q4 2017 in Review

68 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Aurinia Pharmaceuticals (AUPH) for Q4 2017, worth a combined $108M — down 27% from $147M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new AUPH positions and 14 closed out — a net gain of 6 holders — while 17 added to existing stakes and 15 trimmed.

The largest buyer was BlackRock, opening a new position worth an estimated $4M. The largest seller was Fidelity Investments, cutting an estimated $5.74M.

  • 68 institutional investors held Aurinia Pharmaceuticals (AUPH) as of Q4 2017, up from 62 in Q3 2017.
  • Funds reported $108M of Aurinia Pharmaceuticals stock for Q4 2017, down 27% quarter-over-quarter.
  • 20 funds opened new Aurinia Pharmaceuticals positions in Q4 2017 and 14 closed out, a net change of +6 holders.
  • The largest Aurinia Pharmaceuticals buyer in Q4 2017 was BlackRock, an estimated $4M added.
  • The largest Aurinia Pharmaceuticals seller in Q4 2017 was Fidelity Investments, an estimated $5.74M sold.

Based on aggregated 13F filings for Q4 2017.